Abstract
One of the major mechanisms of tumor escape is the inability of antigen presenting cells (APC), and specifically the most potent APC dendritic cells (DC), to induce potent antitumor immune response. The defects in APC are caused by the variety of tumor-derived factors. In this review we will discuss recent findings which indicate that the members of the family of signal transducers and activators of transcription (STATs), and more specifically STAT3, could be responsible for the abnormal DC differentiation and function in cancer. The different approaches to pharmacological regulation of this pathway and their effects on DC function and antitumor immune responses will be discussed.
Keywords: Dendritic cells, T cells, Jak, STAT
Current Cancer Drug Targets
Title: Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer
Volume: 7 Issue: 1
Author(s): Yulia Nefedova and Dmitry I. Gabrilovich
Affiliation:
Keywords: Dendritic cells, T cells, Jak, STAT
Abstract: One of the major mechanisms of tumor escape is the inability of antigen presenting cells (APC), and specifically the most potent APC dendritic cells (DC), to induce potent antitumor immune response. The defects in APC are caused by the variety of tumor-derived factors. In this review we will discuss recent findings which indicate that the members of the family of signal transducers and activators of transcription (STATs), and more specifically STAT3, could be responsible for the abnormal DC differentiation and function in cancer. The different approaches to pharmacological regulation of this pathway and their effects on DC function and antitumor immune responses will be discussed.
Export Options
About this article
Cite this article as:
Nefedova Yulia and Gabrilovich I. Dmitry, Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer, Current Cancer Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/156800907780006887
DOI https://dx.doi.org/10.2174/156800907780006887 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Microbubble: A Potential Ultrasound Tool in Molecular Imaging
Current Pharmaceutical Biotechnology Pt and Pd Based Catalysts with Novel Alloy and Core-Shell Nanostructures for Practical Applications in Next Fuel Cells: Patents and Highlights
Recent Patents on Materials Science Activation of B Cells by a Dendritic Cell-Targeted Oral Vaccine
Current Pharmaceutical Biotechnology Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery From Protein Communication to Drug Discovery
Current Topics in Medicinal Chemistry Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Current Cancer Drug Targets Nanotechnology: A Modern Contraption in Cosmetics and Dermatology
Applied Clinical Research, Clinical Trials and Regulatory Affairs Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery DNA Methylation in Colon Cancer: Challenges and Opportunities
Epigenetic Diagnosis & Therapy (Discontinued) Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3
Current Vascular Pharmacology Preface [Hot Topic: Endocrinology Meets Molecular Oncology: Beyond Radioactive Iodine (Guest Editor: Robert C. Smallridge)]
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Acute Pain Management in Hospitalized Children
Reviews on Recent Clinical Trials A Hopeful Prospect of Riociguat as a Soluble Guanylate Cyclase Stimulator for Management of Pressure Ulcers
Current Drug Discovery Technologies Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Cytotoxic, Antiproliferative and Apoptotic Effects of New Benzimidazole Derivatives on A549 Lung Carcinoma and C6 Glioma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design Roles of Nicotinic Acetylcholine Receptors in Stem Cell Survival/Apoptosis, Proliferation and Differentiation
Current Molecular Medicine